Trial record 5 of 8 for:    NIAID | herpes genitalis

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00495716
Recruitment Status : Active, not recruiting
First Posted : July 3, 2007
Last Update Posted : October 28, 2016
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Anna Wald, University of Washington

Brief Summary:
The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners.

Condition or disease Intervention/treatment Phase
Genital Herpes Drug: acyclovir Phase 4

Detailed Description:
We plan to conduct a randomized controlled trial of chronic suppressive acyclovir, 400 mg orally twice daily (standard dose) versus episodic acyclovir for treatment of genital herpes recurrences. We will enroll 500 HSV-2 seropositive single persons (250 per arm), stratified by gender and history of symptomatic genital herpes, and prospectively follow them for 1 year to assess sexual behavior, adherence to therapy, and herpes-related quality of life. These outcomes will be measured by self-report in a confidential, computer-based assessment. We plan to use data from this trial to model the effect that increasing the proportion of sexually-active HSV-2 infected persons taking suppressive therapy will have on population-level incidence and prevalence of HSV-2.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission
Study Start Date : January 2008
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : July 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Genital Herpes
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Episodic Treatment Arm
800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
Drug: acyclovir
800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
Active Comparator: Suppressive Therapy Arm
400 mg acyclovir orally twice daily for 1 year
Drug: acyclovir
400 mg acyclovir orally twice daily for 1 year

Primary Outcome Measures :
  1. To determine the effect of suppressive antiviral therapy on sexual behavior among HSV-2 seropositive persons with multiple sexual partners. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. To examine the acceptability and adherence to suppressive antiviral therapy for HSV-2 prevention among single, sexually active men and women. [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older
  • HSV-2 seropositive by Western blot OR documented culture positive for HSV-2 from anogenital site
  • 2 or more vaginal or anal sex partners in the past 12 months
  • Not currently in a monogamous sexual relationship of >= 6 months duration
  • Willing and able to be randomized and comply with the study protocol

Exclusion Criteria:

  • Pregnancy or intention to become pregnant within the next year
  • Suppressive therapy with acyclovir, valacyclovir, or famciclovir within 2 weeks of enrollment/randomization
  • 6 or more symptomatic herpes recurrences in the prior 12 months or in the 12 months prior to starting suppressive therapy if on suppressive therapy during the prior 12 months
  • HIV seropositive or known immunocompromising medical condition. HIV negative test must be performed within 60 days of Visit 1 (enrollment/randomization). For current or former participants in HIV vaccine clinical trials for whom HIV vaccine-induced seropositivity potentially leading to vaccine study unblinding may be a concern, a report from the Seattle HVTU documenting that the participant is HIV uninfected based on HIV testing done within 60 days of Visit 1 will be accepted in lieu of HIV testing done at our clinic.
  • Intention to move from the Seattle area within the next year
  • Known allergy, intolerance, or medical contraindication to acyclovir
  • Inability to understand, speak, and read English

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00495716

United States, Washington
University of Washington Virology Research Clinic
Seattle, Washington, United States, 98104
Sponsors and Collaborators
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Anna Wald, MD, MPH University of Washington

Responsible Party: Anna Wald, Principal Investigator, University of Washington Identifier: NCT00495716     History of Changes
Other Study ID Numbers: 32545-B
K23AI071257-01A1 ( U.S. NIH Grant/Contract )
First Posted: July 3, 2007    Key Record Dates
Last Update Posted: October 28, 2016
Last Verified: October 2016

Additional relevant MeSH terms:
Herpes Genitalis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Genital Diseases, Male
Genital Diseases, Female
Antiviral Agents
Anti-Infective Agents